Morepen Posts Record Q1'FY27 Results; Revenue Jumps 34% as CDMO Mandate Enters Full Commercialization

Morepen Posts Record Q1'FY27 Results; Revenue Jumps 34% as CDMO Mandate Enters Full Commercialization​

Morepen Laboratories Limited reported exceptionally strong financial results for the quarter ended June 30, 2026, announcing record-high quarterly revenue and earnings. The company’s performance was driven by improved operating leverage, significant growth in exports, and the successful transition of a major CDMO mandate into full commercialization.

The consolidated financial outcomes reflect substantial profitability improvements across the board, with EBITDA and PAT showing double-digit growth rates.

Key Financial Highlights for Q1'FY27​

CDMO and Strategic Transformation​

A major milestone for Morepen was the entry of its previously announced Rs. 825 Cr CDMO mandate into full-scale commercialization during the quarter. The company reported that it had completed Rs. 58 Cr worth of commercial CDMO dispatches in Q1'FY27. This achievement is viewed as a validation of Morepen’s "Morepen 2.0" strategy, which pivots the business from traditional commodity APIs toward innovation-led manufacturing and long-duration global partnerships.

Commenting on the results, Mr. Sushil Suri, Chairman and Managing Director, stated that Q1 FY27 signifies an important validation of Morepen’s transformation journey, noting the achievement of highest-ever quarterly revenue and meaningful operating leverage. He emphasized that the CDMO mandate's execution reinforces the shift toward a manufacturing-led platform centered on global partnerships.

Sector Performance and Operational Strength​

The company’s API business demonstrated significant strength, recording 31% growth driven by improved product mix, customer prioritization, and operational discipline. Meanwhile, API exports saw strong traction in global markets, increasing by 42%. Management believes this stronger API base will support the transition toward a higher-quality CDMO platform.

The Medical Devices segment provided a scalable source of growth, recording a 19% increase during the quarter. This business focuses on chronic care categories and has established an installed base of 20 million blood glucose meters, supporting an annual strip scale of 500 million strips.

In terms of compliance, Morepen’s quality track record was reinforced by completing four consecutive USFDA inspections with Nil Form 483 observations, bolstering the company’s credibility for long-term CDMO engagements.

Future Growth and Capacity Roadmap​

Looking ahead, Morepen is committed to disciplined execution and capacity expansion. The company is currently expanding its manufacturing capabilities in phases, with a roadmap projecting growth up to 1,200 KL by FY30.

The future growth strategy is built on four pillars: capacity augmentation, global partnerships, capability scale-up, and compliance. The technology roadmap includes deepening expertise in small molecules, process chemistry, complex chemistry, advanced intermediates, and difficult-to-make molecules.

MOREPENLAB Stock Price Movement​

Shares of Morepen Laboratories Limited are surging as of 2:13 PM, rallying by 19.01% to trade at ₹68.61 today. The stock nears its peak performance levels, with the equity trading close to the intraday high of ₹68.89 in live market action.